Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add filters

Database
Language
Document Type
Year range
2.
Clin Pharmacol Ther ; 108(2): 242-247, 2020 08.
Article in English | MEDLINE | ID: covidwho-30729

ABSTRACT

An outbreak of 2019-nCoV infection has spread across the world. No specific antiviral drugs have been approved for the treatment of COVID-2019. In addition to the recommended antiviral drugs, such as interferon-ɑ, lopinavir/ritonavir, ribavirin, and chloroquine phosphate, some clinical trials focusing on virus RNA-dependent RNA polymerase (RdRp) inhibitors have been registered and initiated. Favipiravir, a purine nucleic acid analog and potent RdRp inhibitor approved for use in influenza, is also considered in several clinical trials. Herein, we summarized the pharmacokinetic characteristics of favipiravir and possible drug-drug interactions from the view of drug metabolism. We hope this will be helpful for the design of clinical trials for favipiravir in COVID-2019, as data regarding in vitro virus inhibition and efficacy in preclinical animal studies are still not available.


Subject(s)
Amides/pharmacokinetics , Antiviral Agents/pharmacokinetics , Pyrazines/pharmacokinetics , Acetaminophen/pharmacokinetics , Amides/administration & dosage , Amides/blood , Animals , Antiviral Agents/administration & dosage , Antiviral Agents/blood , COVID-19/drug therapy , Clinical Trials as Topic , Coronavirus Infections/drug therapy , Drug Interactions , Humans , Pyrazines/administration & dosage , Pyrazines/blood
SELECTION OF CITATIONS
SEARCH DETAIL